Amylyx Pharmaceuticals, Inc. AMLX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$150.11M-3.7% | -$144.74M+3.0% | -$149.28M+20.4% | -$187.6M+14.3% | -$218.86M+27.5% | ||
| $467K-11.0% | $525K-9.0% | $577K-14.9% | $678K-9.0% | $745K-17.6% | ||
| $26.93M-2.6% | $27.65M-1.3% | $28M+1.0% | $27.73M-7.4% | $29.95M-9.4% | ||
| —— | —— | —— | —— | -$18.05M+12.3% | ||
| —— | —— | —— | —— | -$63.92M-6.9% | ||
| —— | —— | —— | —— | —— | ||
| $116K-31.4% | $169K+143% | -$395K0.0% | -$395K+57.8% | -$936K+2.3% | ||
| -$913K+23.0% | -$1.19M+33.1% | -$1.77M+23.6% | -$2.32M-0.3% | -$2.31M-2.5% | ||
| -$120.4M+2.4% | -$123.34M+20.1% | -$154.45M+6.8% | -$165.65M+20.0% | -$206.98M-23.5% | ||
| —— | $138K+91.7% | $72K— | —— | —— | ||
| $147.91M-36.2% | $231.82M— | —— | —— | —— | ||
| —— | —— | —— | —— | $31.18M-58.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $65.88M+18,831% | ||
| $766K-28.7% | $1.07M+149% | $431K-16.5% | $516K+494% | -$131K+70.1% | ||
| $168.91M+13.5% | $148.8M+1.0% | $147.32M+778% | -$21.74M+81.2% | -$115.62M-18.4% | ||
| $4.43M-19.8% | $5.53M-11.7% | $6.26M-14.5% | $7.32M-18.4% | $8.98M-8.9% | ||
| —— | —— | —— | —— | —— | ||
| $467K-11.0% | $525K-9.0% | $577K-14.9% | $678K-9.0% | $745K-17.6% | ||
| —— | $1.98M+50.5% | $1.31M+102% | $649.5K+4,824% | -$13.75K+98.0% | ||
| -$913K+23.0% | -$1.19M+33.1% | -$1.77M+23.6% | -$2.32M-0.3% | -$2.31M-2.5% | ||
| $1.52M-12.4% | $1.73M-10.8% | $1.94M-7.5% | $2.1M+5.0% | $2M+2.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $116K-31.4% | $169K+143% | -$395K0.0% | -$395K+57.8% | -$936K+2.3% | ||
| —— | —— | —— | —— | —— | ||
| $10.27M+152% | $4.08M+5.9% | $3.85M+129% | $1.68M+1.5% | $1.66M-22.3% | ||
| $6.42M+91.0% | $3.36M+5.4% | $3.19M+122% | $1.44M+6.1% | $1.35M-24.1% | ||
| -$913K+23.0% | -$1.19M+33.1% | -$1.77M+23.6% | -$2.32M-0.3% | -$2.31M-2.5% | ||
| —— | -$123.48M+20.1% | -$154.52M+6.7% | -$165.68M+20.0% | -$207.08M-23.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amylyx Pharmaceuticals, Inc. generate?
- Amylyx Pharmaceuticals, Inc. (AMLX) generated -$120.4M in operating cash flow over the trailing twelve months.
- What is Amylyx Pharmaceuticals, Inc.'s free cash flow?
- After $138.0K of capital expenditures, Amylyx Pharmaceuticals, Inc.'s free cash flow was -$123.5M over the trailing twelve months, up 26.4% year over year.
- Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.